Inoculation of human tumor cells alters the basal expression but not the inducibility of cytochrome P450 enzymes in tumor-bearing mouse liver

Drug Metabolism and Disposition

Volumn 37, Issue 11, 2009, Pages 2244-2254

  Sugawara, Michiko ^a   Okamoto, Kiyoshi ^a   Kadowaki, Tadashi ^a   Kusano, Kazutomi ^a   Fukamizu, Akiyoshi ^b   Yoshimura, Tsutomu ^a  

^a EISAI CO LTD   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 2B; CYTOCHROME P450 3A; DEXAMETHASONE; DRUG METABOLIZING ENZYME; PACLITAXEL; PHENOBARBITAL;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; INOCULATION; LIVER; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 70350310095     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.028571     Document Type: Article

References (38)

1. Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, and Robertson GR (2006) Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res 12:7492-7497. (Pubitemid 46095425)
2. Choudhary D, Jansson I, Schenkman JB, Sarfarazi M, and Stoilov I (2003) Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch Biochem Biophys 414:91-100. (Pubitemid 36555449)
3. Down MJ, Arkle S, and Mills JJ (2007) Regulation and induction of CYP3A11, CYP3A13 and CYP3A25 in C57BL/6J mouse liver. Arch Biochem Biophys 457:105-110. (Pubitemid 46001772)
4. Gauchez AS, Riondel J, Jacrot M, Calop J, and Favier A (1995) Antioxidant status and lipid peroxidation in athymic mice xenografted with two types of human tumors. Biol Trace Elem Res 47:103-109.
5. Harmsen S, Meijerman I, Beijnen JH, and Schellens JH (2007) The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat Rev 33:369-380. (Pubitemid 46760528)
6. Hernandez JP, Mota LC, Huang W, Moore DD, and Baldwin WS (2009) Sexually dimorphic regulation and induction of P450s by the constitutive androstane receptor (CAR). Toxicology 256:53-64.
7. Hewitt NJ, Lecluyse EL, and Ferguson SS (2007) Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 37:1196-1224.
8. Hill SA and Denekamp J (1982) Site dependent response of tumours to combined heat and radiation. Br J Radiol 55:905-912.
9. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, et al. (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662-670. (Pubitemid 351713150)
10. Islam R, Anzai N, Ahmed N, Ellapan B, Jin CJ, Srivastava S, Miura D, Fukutomi T, Kanai Y, and Endou H (2008) Mouse organic anion transporter 2 (mOat2) mediates the transport of short chain fatty acid propionate. J Pharmacol Sci 106:525-528.
11. Keyes KA, Mann L, Cox K, Treadway P, Iversen P, Chen YF, and Teicher BA (2003a) Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemother Pharmacol 51:321-327. (Pubitemid 36629810)
12. Keyes KA, Mann L, Teicher B, and Alvarez E (2003b) Site-dependent angiogenic cytokine production in human tumor xenografts. Cytokine 21:98-104. (Pubitemid 36369396)
13. Lee CM, Pohl J, and Morgan ET (2009) Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures. Drug Metab Dispos 37:865-872.
14. Lin JH (2006) CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 23:1089-1116.
15. Löfgren S, Hagbjörk AL, Ekman S, Fransson-Steen R, and Terelius Y (2004) Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison. Xenobiotica 34:811-834. (Pubitemid 39546271)
16. Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, et al. (2005a) Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother Pharmacol 56:455-464. (Pubitemid 41549146)
17. Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, et al. (2005b) Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model. Clin Cancer Res 11:5558-5565. (Pubitemid 41060833)
18. MacLeod SL, Nowell S, Massengill J, Jazieh A, McClure G, Plaxco J, Kadlubar FF, and Lan NP (2000) Cancer therapy and polymorphisms of cytochromes P450. Clin Chem Lab Med 38:883-887. (Pubitemid 30814770)
19. Malavé I, Blanca I, and Fuji H (1979) Influence of inoculation site on development of the Lewis lung carcinoma and suppressor cell activity in syngeneic mice. J Natl Cancer Inst 62:83-88. (Pubitemid 9083808)
20. Martignoni M, de Kanter R, Grossi P, Saturno G, Barbaria E, and Monshouwer M (2006) An in vivo and in vitro comparison of CYP gene induction in mice using liver slices and quantitative RT-PCR. Toxicol In Vitro 20:125-131. (Pubitemid 41796450)
21. Martignoni M, de Kanter R, Moscone A, Grossi P, and Monshouwer M (2005) Lack of strain-related differences in drug metabolism and efflux transporter characteristics between CD-1 and athymic nude mice. Cancer Chemother Pharmacol 55:129-135. (Pubitemid 40110055)
22. Muller DN, Schmidt C, Barbosa-Sicard E, Wellner M, Gross V, Hercule H, Markovic M, Honeck H, Luft FC, and Schunck WH (2007) Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J 403:109-118. (Pubitemid 46569872)
23. Nakata K, Tanaka Y, Nakano T, Adachi T, Tanaka H, Kaminuma T, and Ishikawa T (2006) Nuclear receptor-mediated transcriptional regulation in Phase I, II, and III xenobiotic metabolizing systems. Drug Metab Pharmacokinet 21:437-457.
24. Nallani SC, Goodwin B, Maglich JM, Buckley DJ, Buckley AR, and Desai PB (2003) Induction of cytochrome P450 3A by paclitaxel in mice: pivotal role of the nuclear xenobiotic receptor, pregnane X receptor. Drug Metab Dispos 31:681-684. (Pubitemid 36444179)
25. Rizwan AN and Burckhardt G (2007) Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 24:450-470. (Pubitemid 46295167)
26. Rolstad B (2001) The athymic nude rat: an animal experimental model to reveal novel aspects of innate immune responses? Immunol Rev 184:136-144.
27. Sharma R, Kacevska M, London R, Clarke SJ, Liddle C, and Robertson G (2008) Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies. Br J Cancer 98:91-97.
28. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, and Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094-1101. (Pubitemid 38176915)
29. Simpson AE (1997) The cytochrome P450 4 (CYP4) family. Gen Pharmacol 28:351-359.
30. Talmadge JE, Singh RK, Fidler IJ, and Raz A (2007) Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 170:793-804.
31. Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW, and Frei E 3rd (1990) Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247:1457-1461.
32. Xu C, Li CY, and Kong AN (2005) Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharmacol Res 28:249-268. (Pubitemid 44698742)
33. Yuan W, Cawley GF, Eyer CS, and Backes WL (1994) Induction of P450 3A by ethylbenzene without altering RNA levels. Biochem Biophys Res Commun 202:1259-1265. (Pubitemid 24265903)
34. Zangar RC, Bollinger N, Verma S, Karin NJ, and Lu Y (2008) The nuclear factor-κB pathway regulates cytochrome P450 3A4 protein stability. Mol Pharmacol 73:1652-1658. (Pubitemid 351724354)
35. Zangar RC, Hernandez M, and Novak RF (1997) Posttranscriptional elevation of cytochrome P450 3A expression. Biochem Biophys Res Commun 231:203-205. (Pubitemid 27212138)
36. Zhou C, Tabb MM, Nelson EL, Grün F, Verma S, Sadatrafiei A, Lin M, Mallick S, Forman BM, Thummel KE, et al. (2006) Mutual repression between steroid and xenobiotic receptor and NF-κB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest 116:2280-2289. (Pubitemid 44162338)
37. Zimmermann C, van Waterschoot RA, Harmsen S, Maier A, Gutmann H, and Schinkel AH (2009) PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci 2:565-571.
38. Zordoky BN and El-Kadi AO (2009) Role of NF-κB in the regulation of cytochrome P450 enzymes. Curr Drug Metab 10:164-178.